BIOCOMPATIBLE STRUCTURES AND COMPOSITIONS

• US 20110196489A1
• Filed: 02/04/2011
• Published: 08/11/2011
• Est. Priority Date: 02/05/2010
• Status: Active Grant

• Current Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Original Assignee: Allergan, Inc. (Canada) (Abbvie Incorporated)
• Inventors: Ren, Cindy D., Thompson, Jordan M., Goraltchouk, Alexei, Van Epps, Dennis E.
• Granted Patent: US 9,072,821 B2
• Time in Patent Office: Days
• US Class Current: 623/8
• CPC Class Codes: A61F 2/12 Mammary prostheses and implants
• CPC Class Codes: A61L 2430/04 for mammary reconstruction
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: C08L 83/04 Polysiloxanes
• CPC Class Codes: Y10T 428/26 Web or sheet containing structurally defined element or component, the element or component having a specified physical dimension
• CPC Class Codes: Y10T 428/269 including synthetic resin or polymer layer or component

Abstract

Described herein are material compositions including various textures which when implanted in a mammal encourage an optimal biological response.

Claims

1. An inverse foam having a pore size of about 400 μ

m to about 550 μ

m and an interconnection size of about 150 μ

m to about 300 μ

m, wherein said foam, upon implantation, results in substantial tissue ingrowth, minimal capsular formation and/or substantial tissue adhesion.

2. The inverse foam according to claim 1 wherein said inverse foam is biodegradable.

3. The inverse foam according to claim 1 wherein said inverse foam is non-biodegradable.

4. The inverse foam according to claim 1 wherein said pore size is about 470 μ

m.

5. The inverse foam according to claim 1 wherein said interconnection size is about 210 μ

m.

6. The inverse foam according to claim 1 wherein said inverse foam is coated on an implantable medical device.

7. The inverse foam according to claim 6 wherein said implantable medical device is a soft tissue implant.

8. The inverse foam according to claim 7 wherein soft tissue implant is a breast implant.

9. The inverse foam according to claim 1 wherein said optimal biological response includes at least one of substantial tissue ingrowth, minimal capsular formation and tissue adhesion.

10. The inverse foam according to claim 1 wherein the inverse foam is silicone.

11. An implant having an outer surface comprising a fibrous felt material having a structure such that upon implantation of the implant, the fibrous felt encourages substantial tissue ingrowth, minimal capsular formation and/or substantial tissue adhesion.